Gland B2B Business Model and Growth Strategy
Journey
Launch of Enoxaparin Sodium
Injection (Cutenox) in India
and Rest of the world markets
Incorporation
by P.V.N. Raju
Received USFDA
approval for the
facility at Dundigal
manufacturing
Launched Heparin
Sodium Injection
in the US
BGV Hamburg
(Germany)
approval for
Dundigal facility
Received ANDA approval for Enoxaparin Sodium Injection USP
Received ANDA approval for first Ophthalmic product
USFDA and EU
approval for
Oncology plant,
Vishakhapatnam
SEZ
Filed first ANDA
from Penems
facility
USFDA approval for facilities
at Visakhapatnam,
Visakhapatnam SEZ and the
manufacturing facility at
Pashamylaram
Commenced commercial
sales in the US from
Pashamylaram facility
First OTC launch in
US market for
Olopatadine
ophthalmic solution
Listed on Indian
stock exchanges,
NSE & BSE
14
1978
2000
2003
2004-05
2007
2010
2012
2014
2016
2018
2017
2020
2021
2019
Set up In-house R&D
facility at Dundigal,
Hyderabad
Capital infusion of
~1,000 million pursuant
to PE investment
Commissioned
Pashamylaram unit
Land leased at
Vishakhapatnam SEZ on
which Oncology facility
and API facilities situated
PE investment of US$
200mn from KKR
Fosun Singapore
acquired 74%
stake
Commission of Asset
First filing with
National Medical
Products
Administration,
China, and received
clinical waiver for
Dexrazoxane
Investor/Capital Infusion
Purchased assets of
Vitane Biologics,
Hyderabad based
biopharmaceutical
company
Entered agreement with
RDIF to supply upto
252 million doses of
Sputnik V COVID-19
vaccine
Launch/Filings
GLANDView entire presentation